Instituto Rosenbusch S.A. (ROSE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Instituto Rosenbusch S.A. stock ARS 254, price ARS 138, upside +84.1%, quality 34 out of 100. Rating: strongly undervalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range 9.10 ARS – 380.00 ARS · fair‑value band 200.95 ARS – 319.17 ARS · the 138.00 ARS price screens below the 254.01 ARS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Instituto Rosenbusch in your weekly email
Every Wednesday you see whether Instituto Rosenbusch is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina.
Show moreShow less
The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis.
It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals.
The company was founded in 1917 and is based in Buenos Aires, Argentina.
Stock analysis
Instituto Rosenbusch S.A. (ROSE) currently trades at 138.00 ARS, while our model-based Fair Value estimate is 254.01 ARS, implying the stock looks roughly 46% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 267.89 ARS per share, and 5 of the 6 models we run sit above the 138.00 ARS price.
Bear case: the Multiples group reads lowest at 104.10 ARS, and 1 of the 6 models stay below the price. Data coverage for this calculation is low.
Scenario range: 200.95 ARS (bear) to 319.17 ARS (bull), the price of 138.00 ARS sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Instituto Rosenbusch S.A. reported revenue of 6.4B ARS in FY2025 versus 782M ARS in FY2021, a compound +69.2%/yr. Reported net income was −4.6B ARS in FY2025.
Key figures
Market cap 5.9B ARS (≈ $3.8M) Micro · P/E ratio 0.7 · P/S ratio 0.85 · EPS (TTM) 197.76 ARS · Net margin −71.8% · Return on equity 5.5% · Return on assets (EBIT) 1.8% (5-year average) · Operating margin −27.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).
What moves the price
The share trades about 58% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 84%, ROSE screens cheaper than that median.
Fair Value models
Bear200.95 ARSFair Value 254.01 ARSBull319.17 ARS
Price 138.00 ARS · Upside +84.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (169.59 ARS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−41.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+67.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+62.9%
Start year 2020 (pandemic). Over 10 years: +47.0% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.1% (2020) → −49.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Argentina: IMF forecast 13.8% a year to 2030) that is about +7.5% a year for the price.
Compare Instituto Rosenbusch S.A. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score34 · Bottom 25%
Fair Value upside+84.1% · Top 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−59.4% · Bottom 25%
Net margin (12 months)2.7% · Below median
Operating margin (12 months)−27.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)15.3% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)0.7× · Cheapest 25%
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 15
FUTURE (revenue growth)77· sector 25
PAST (return on equity)0· sector 29
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Instituto Rosenbusch S.A. (ROSE) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 254.01 ARS versus a price of 138.00 ARS, about +84% upside (undervalued).
What is the fair value of ROSE?
Our model-based fair value for Instituto Rosenbusch S.A. is 254.01 ARS (as of Nov 7, 2026), built from audited fundamentals. The current price: 138.00 ARS.
What is the quality score of ROSE?
Instituto Rosenbusch S.A. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Instituto Rosenbusch S.A. (ROSE)?
Our model-based price target is the fair value of 254.01 ARS (as of Nov 7, 2026) from 6 valuation models. Cautious scenario 200.95 ARS, optimistic scenario 319.17 ARS. It is a calculation from audited fundamentals, not an analyst target.
What is the Instituto Rosenbusch S.A. stock forecast for 2026?
Our models put fair value at 254.01 ARS, about +84% upside versus a price of 138.00 ARS (undervalued). Cautious scenario 200.95 ARS, optimistic scenario 319.17 ARS. The calculation is refreshed regularly with new filings.
What is the revenue of Instituto Rosenbusch S.A. (ROSE)?
Instituto Rosenbusch S.A. reported trailing-twelve-month revenue of about 6.8B ARS (latest available figure, as of Nov 7, 2026).
What growth is priced into Instituto Rosenbusch S.A. (ROSE)?
For today's price to be fair in a discounted-cash-flow model, Instituto Rosenbusch S.A. would have to grow free cash flow by +22.4 % per year for five years (discount rate 17.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +62.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ROSE use?
Our models discount Instituto Rosenbusch S.A. at 17.7 %: a base by market capitalisation (nano), damped by beta 0.03, country premium for Argentina. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Instituto Rosenbusch S.A. that is +22.4 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (17.7 %) and the same formula as our fair value.
How much growth has Instituto Rosenbusch S.A. (ROSE) delivered so far?
Over the past 5 years revenue at Instituto Rosenbusch S.A. grew +62.9 % a year. The price currently implies free-cash-flow growth of +22.4 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Instituto Rosenbusch S.A. (ROSE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Instituto Rosenbusch S.A. (+22.4 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Instituto Rosenbusch S.A. (ROSE)?
The free-cash-flow yield on the price is 6.77 %: that much free cash flow Instituto Rosenbusch S.A. produces per unit of market value. When it exceeds the discount rate of our models (17.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Instituto Rosenbusch S.A. (ROSE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Instituto Rosenbusch S.A. it is 254.01 ARS per share (as of Nov 7, 2026), against a price of 138.00 ARS. It is the blended result of 6 valuation models in 3 families (DCF Models, Multiples, Growth DCF).
Is Instituto Rosenbusch S.A. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ROSE trades below its calculated fair value: price 138.00 ARS, fair value 254.01 ARS, a gap of about +84% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROSE?
No. The price is what the market pays today (138.00 ARS); the fair value is what the company's own numbers justify (254.01 ARS). For Instituto Rosenbusch S.A. the two are 116.01 ARS per share apart. That gap is exactly why we show both numbers side by side.
How much is Instituto Rosenbusch S.A. worth?
The market values Instituto Rosenbusch S.A. at about 5.9B ARS (market capitalisation, as of Nov 7, 2026). Per share that is 138.00 ARS; our models calculate a fair value of 254.01 ARS per share.
What do the bullish and bearish scenarios say about ROSE?
Our models span a range for Instituto Rosenbusch S.A.: cautious scenario 200.95 ARS, base 254.01 ARS, optimistic 319.17 ARS per share (as of Nov 7, 2026, price 138.00 ARS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ROSE?
Instituto Rosenbusch S.A. trades at a price-to-earnings ratio of 0.7 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 254.01 ARS is built from several models across several years.
How solid is the balance sheet of Instituto Rosenbusch S.A. (ROSE)?
Balance-sheet figures for Instituto Rosenbusch S.A. (as of Nov 7, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is ROSE from its 52-week high?
Instituto Rosenbusch S.A. trades at 138.00 ARS, about 58% below its 52-week high of 327.00 ARS and 2% above the low of 135.50 ARS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 254.01 ARS is for.
Which stocks are comparable to Instituto Rosenbusch S.A.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Instituto Rosenbusch S.A. stock attractive at the current price?
The data as of Nov 7, 2026: price 138.00 ARS, calculated fair value 254.01 ARS (+84%), Quality Score 34/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ROSE calculated?
We run Instituto Rosenbusch S.A. through 6 models from 3 families: DCF Models, Multiples, Growth DCF. Every model gets the same audited fundamentals; the fair value of 254.01 ARS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Instituto Rosenbusch S.A. currently trades 46% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Instituto Rosenbusch S.A. (ROSE)?
The closing price on Nov 6, 2026 was 138.00 ARS. Our model-based fair value is 254.01 ARS, about +84% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Instituto Rosenbusch S.A. right now?
The large discount to fair value meets weak quality (34/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (200.95 ARS). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Instituto Rosenbusch S.A.
How large is the market capitalisation of Instituto Rosenbusch S.A. (ROSE)?
The market capitalisation of Instituto Rosenbusch S.A. is 5.9B ARS (≈ $3.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Instituto Rosenbusch S.A. (ROSE)?
The price-to-sales ratio of Instituto Rosenbusch S.A. is 0.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Instituto Rosenbusch S.A. (ROSE)?
Earnings per share at Instituto Rosenbusch S.A. are 197.76 ARS (price ÷ EPS = P/E 0.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Instituto Rosenbusch S.A. (ROSE)?
The net margin of Instituto Rosenbusch S.A. is −71.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Instituto Rosenbusch S.A. (ROSE)?
The return on equity (ROE) of Instituto Rosenbusch S.A. is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Instituto Rosenbusch S.A. (ROSE)?
On an EBIT basis the return on assets of Instituto Rosenbusch S.A. is 1.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Instituto Rosenbusch S.A. (ROSE)?
The operating margin of Instituto Rosenbusch S.A. is −27.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Instituto Rosenbusch S.A. (ROSE)?
Revenue at Instituto Rosenbusch S.A. is growing +15.3% versus a year earlier (3y avg +67.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Instituto Rosenbusch S.A. (ROSE)?
Earnings per share at Instituto Rosenbusch S.A. are growing −86.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Instituto Rosenbusch S.A. (ROSE) carry?
The net debt of Instituto Rosenbusch S.A. is 738M ARS (fiscal year 2025, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Instituto Rosenbusch S.A. in the live analysis
One click puts Instituto Rosenbusch S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026